<DOC>
	<DOCNO>NCT01421862</DOCNO>
	<brief_summary>RATIONALE : Studying sample bone marrow blood patient cancer fail treatment may help doctor learn change occur DNA identify biomarkers related cancer resistance . It may also help doctor find good way treat cancer . PURPOSE : This research trial study biomarkers sample adult patient acute myeloid leukemia fail standard-of-care treatment .</brief_summary>
	<brief_title>Biomarkers Samples From Adult Patients With Acute Myeloid Leukemia Who Failed Existing Standard-of-Care Treatment</brief_title>
	<detailed_description>OBJECTIVES : - Define `` non-response '' signature help up-front identification case intermediate-risk acute myeloid leukemia ( AML ) destine fail exist standard-of-care therapy . - Identify biological pathway `` non-response '' group provide target novel therapeutic . OUTLINE : DNA RNA extract cryopreserved bone marrow cell and/or blood cell analyze mutation gene expression signature ( genome-wide methylation , mRNA miRNA expression , single nucleotide polymorphism ( SNP ) analysis ) microarray assay .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Samples previously untreated nonM3 acute myeloid leukemia ( AML ) Normal karyotype ( NK ) intermediaterisk disease Two vial cryopreserved pretreatment bone marrow cell and/or two vial cryopreserved pretreatment blood cell available Intergroup AML Repository Blast count â‰¥ 60 % Eligible evaluable patient 's clinical trial , fatal induction toxicity Response protocol induction chemotherapy : Nonresponse : AML failure achieve complete remission ( CR ) induction chemotherapy ( `` 7 &amp; 3 '' base therapy use cytatabine and/or daunorobicin hydrochloride ( DNR ) OR idarubicin and/or DNR Responders : continue complete remission ( CCR ) &gt; 2 year PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia del ( 5q )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
</DOC>